
Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
7 Fun Plans to Make Film Evenings Seriously Energizing (You'll Cherish #5!) - 2
Photos of amputees in Gaza, struggling to survive after losing limbs to Israeli airstrikes - 3
Artemis 2 astronauts are now headed to the moon. Why has it taken humanity so long to go back? - 4
Prehistoric wolf’s gut frozen in time reveals an ice age giant - 5
Guinea-Bissau's coup called a 'sham' by West African political figures
The Best Web-based Courses for Ability Advancement
The Most Astonishing Arising Advancements to Watch
Best Getaway destination: Ocean side, Mountain, or City
St George Mining hits record 178m high-grade intercept at Araxá, reinforcing global scale
The Difficulties of Getting a Green Card in the US
Palestinian leader Abbas says elections only after Gaza war ends
Italy Brings In New Measures In 2026 To Tackle Overtourism
'Unreal' solar eclipse: Artemis 2 crew just saw one of the rarest sights in spaceflight history
Manual for Vegetarian Protein Powder













